Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

2,059

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
HIV Prevention
Interventions
DRUG

Tenofovir gel

Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.

DRUG

Universal placebo gel

The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel

Trial Locations (9)

316

MatCH Edendale Research Center, Pietermaritzburg

3370

Qhakaza Mbokodo Research Clinic, Ladysmith

Unknown

Desmond Tutu HIV Centre / University of Cape Town, Cape Town

Perinatal HIV Research Unit / University of the Witwatersrand, Diepkloof

Wits Reproductive Health and HIV Institute / University of the Witwatersrand, Hillbrow

Medunsa Clinical Research Unit / Ga-Ra, Pretoria

The Aurum Institute (Rustenburg), Rustenburg

Setshaba Research Centre, Soshanguve

The Aurum Institute, Tembisa Hospital, Tembisa

All Listed Sponsors
collaborator

Follow-on African Consortium for Tenofovir Studies (FACTS)

UNKNOWN

collaborator

United States Agency for International Development (USAID)

FED

lead

CONRAD

OTHER

NCT01386294 - Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection | Biotech Hunter | Biotech Hunter